Third, we need prospective cohort studies to clarify whether baseline circulating adiponectin and/or hepatic (in HCC and the adjacent non-cancerous tissue) adiponectin may serve as positive or negative predictors of the survival in NAFLD-associated HCC. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.